Watchlist Price Alert

Exact Sciences Corporatio... (EXAS)

NASDAQ: EXAS · Real-Time Price · USD

53.52

-0.49 (-0.91%)

At close: Jun 13, 2025, 3:59 PM

53.87

0.65%

After-hours: Jun 13, 2025, 05:12 PM EDT

-0.91% (1D)

Bid	52.51
Market Cap	10.1B
Revenue (ttm)	2.83B
Net Income (ttm)	-1.02B
EPS (ttm)	-5.53
PE Ratio (ttm)	-9.68
Forward PE	145.86
Analyst	Buy

Ask	55
Volume	1,079,468
Avg. Volume (20D)	2,814,404
Open	53.20
Previous Close	54.01
Day's Range	53.08 - 54.20
52-Week Range	39.97 - 72.83
Beta	0.98

About EXAS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EXAS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EXAS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+9.31%

Exact Sciences shares are trading higher after the... Unlock content with Pro Subscription

1 month ago

+3.33%

Exact Sciences shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY25 sales guidance.

News

1 week ago · zacks.com

Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?

EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.

2 weeks ago · businesswire.com

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinica...

2 weeks ago · businesswire.com

Exact Sciences to Participate in June Investor Conference

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow...

3 weeks ago · businesswire.com

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Soc...

1 month ago · fool.com

2 Brilliant Stocks to Buy With $200 and Hold for 5 Years

While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significa...

1 month ago · businesswire.com

Exact Sciences Earns 2025 Great Place To Work® Certification™

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® fo...

1 month ago · seekingalpha.com

Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling

Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue de...

1 month ago · benzinga.com

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents.